Alembic Pharma (Alembic) reported a strong performance for 2QFY2012. The companys growth was driven by exports and the domestic formulation business (which performed better than others), as restructuring of the business segment has now started showing results. Alembic reported robust sales growth and improvement in the OPM. At the CMP, the stock is trading at attractive valuations. Hence, we maintain our Buy view on the stock.

Download Full Report View Full Report in Browser